Duopharma Biotech Bhd
KLSE:DPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.11
1.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MYR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
DPHARMA Price Targets Summary
Duopharma Biotech Bhd
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.72 MYR with a low forecast of 1.62 MYR and a high forecast of 1.83 MYR.
Operating Income
Forecast
Operating Income Estimate
Duopharma Biotech Bhd
For the last 13 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 9%. The projected CAGR for the next 3 years is 16%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is DPHARMA's stock price target?
Price Target
1.72
MYR
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.72 MYR with a low forecast of 1.62 MYR and a high forecast of 1.83 MYR.
What is Duopharma Biotech Bhd's Revenue forecast?
Projected CAGR
8%
For the last 13 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 15%. The projected CAGR for the next 3 years is 8%.
What is Duopharma Biotech Bhd's Operating Income forecast?
Projected CAGR
16%
For the last 13 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 9%. The projected CAGR for the next 3 years is 16%.
What is Duopharma Biotech Bhd's Net Income forecast?
Projected CAGR
21%
For the last 13 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 7%. The projected CAGR for the next 3 years is 21%.
